$0.15
(Market cap
$49 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
0.4
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.5 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
0.4
-
Debt to Equity
--
-
Book Value
$--
-
EPS
$--
-
Face value
--
-
Shares outstanding
5,043,360
6 Years Aggregate
CFO
$-451.85 Mln
EBITDA
$-619.52 Mln
Net Profit
$-623.68 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Allovir Inc (ALVR)
| 2,235.7 | -0.9 | 2,046.6 | 1,159.5 | 5.2 | -- | -- |
|
BSE Sensex*
| -11.1 | -4.0 | -9.7 | -8.5 | 7.0 | 8.7 | 11.3 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
|---|---|---|---|---|
|
Allovir Inc (ALVR)
| -38.0 | -86.7 | -60.4 | -66.3 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Shareholding Pattern
View DetailsAbout Allovir Inc (ALVR)
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead... product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. The company was incorporated in 2013 and is based in Waltham, Massachusetts. Read more
-
Executive Chairman of the Board
Mr. David L. Hallal
-
Executive Chairman of the Board
Mr. David L. Hallal
-
Headquarters
Waltham, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Allovir Inc (ALVR)
What is the current share price of Allovir Inc (ALVR) Today?
The share price of Allovir Inc (ALVR) is $9.81 (NASDAQ) as of 18-Mar-2025 16:00 EDT. Allovir Inc (ALVR) has given a return of 5.23% in the last 3 years.
What is the current PB & PE ratio of Allovir Inc (ALVR)?
Since, TTM earnings of Allovir Inc (ALVR) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2024
|
--
|
--
|
|
2023
|
--
|
--
|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
|
2020
|
--
|
--
|
What is the 52 Week High and Low of Allovir Inc (ALVR)?
The 52-week high and low of Allovir Inc (ALVR) are Rs -- and Rs -- as of 18-May-2026.
What is the market cap of Allovir Inc (ALVR)?
Allovir Inc (ALVR) has a market capitalisation of $ 49 Mln as on 19-Mar-2025. As per SEBI classification, it is a Small Cap company.
Should I invest in Allovir Inc (ALVR)?
Before investing in Allovir Inc (ALVR), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.